Epstein–Barr virus infection: Basis of malignancy and potential for therapy

Expert Reviews in Molecular Medicine

Volumn 3, Issue 28, 2001, Pages 1-20

  Murray, Paul G ^a   Young, Lawrence S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012499638     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399401003842     Document Type: Article

References (123)

1. Yao, Q.Y., Rickinson, A.B. and Epstein, M.A. (1985) A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 35, 35–42, PubMed ID: 85103938
2. Knox, P.G. and Young, L.S. (1995) Epstein-Barr virus infection of CR2-transfected epithelial cells reveals the presence of MHC class II on the virion. Virology 213, 147–157, PubMed ID: 96036489
3. Rickinson, A.B. et al. (1984) T-cell-mediated regression of “spontaneous” and of Epstein-Barr virus- induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol 87, 646–658, PubMed ID: 84282797
4. Kieff, E. (1996) Epstein-Barr virus and its replication. In Virology (3rd edn) (Fields, B.N., Knipe, D.M. and Howley, P.M., eds), pp. 2343–2396, Lipincott-Raven Publishers, New York
5. Brooks, L.A. et al. (1993) Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 67, 3182–3190, PubMed ID: 93267765
6. Speck, S.H. and Strominger, J.L. (1989) Transcription of Epstein-Barr virus in latently infected, growth-transformed lymphocytes. Adv Viral Oncol 8, 133–150
7. Rowe, M. et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. Embo J 6, 2743–2751, PubMed ID: 88054972
8. Wang, F. et al. (1987) Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A 84, 3452–3456, PubMed ID: 87204155
9. Ernberg, I. and Andersson, J. (1986) Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. J Gen Virol 67, 2267–2272, PubMed ID: 87010563
10. Yao, Q.Y. et al. (1989) Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 43, 67–71, PubMed ID: 89092484
11. Gratama, J.W. et al. (1990) Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients [published erratum appears in Transplantation 1990, 50, 910].
12. Transplantation 49, 725–730, PubMed ID: 90223546
13. Young, L.S. (1999) Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health. Lancet 354, 1141–1142, PubMed ID: 99441862
14. Babcock, G.J. et al. (1998) EBV persistence in memory B cells in vivo. Immunity 9, 395–404, PubMed ID: 98439695
15. Joseph, A.M., Babcock, G.J. and Thorley-Lawson, D.A. (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74, 9964–9971, PubMed ID: 20481635
16. Babcock, G.J. and Thorley-Lawson, D.A. (2000) Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A 97, 12250–12255, PubMed ID: 20504496
17. Uchida, J. et al. (1999) Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286, 300–303, PubMed ID: 99445922
18. De Souza, Y.G. et al. (1989) Localization of Epstein-Barr virus DNA in the epithelial cells of oral hairy leukoplakia by in situ hybridization of tissue sections. N Engl J Med 320, 1559–1560, PubMed ID: 89261949
19. Niedobitek, G. et al. (2000) Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol Pathol 53, 37–42, PubMed ID: 20343334
20. Sam, C.K. et al. (1993) Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int J Cancer 53, 957–962, PubMed ID: 93231699
21. Gulley, M.L. et al. (1996) Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 27, 20–27, PubMed ID: 96144773
22. Pathmanathan, R. et al. (1995) Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333, 693–698, PubMed ID: 95364885
23. Takada, K. (2000) Epstein-Barr virus and gastric carcinoma. Mol Pathol 53, 255–261, PubMed ID: 20543342
24. Nonkwelo, C. et al. (1996) Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70, 623–627, PubMed ID: 96099482
25. Levitskaya, J. et al. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685–688, PubMed ID: 95312106
26. Wilson, J.B., Bell, J.L. and Levine, A.J. (1996) Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J 15, 3117–3126, PubMed ID: 96272171
27. Hammerschmidt, W. and Sugden, B. (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340, 393–397, PubMed ID: 89330563
28. Grossman, S.R. et al. (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A 91, 7568–7572, PubMed ID: 94329557
29. Artavanis-Tsakonas, S., Matsuno, K. and Fortini, M.E. (1995) Notch signaling. Science 268, 225–232, PubMed ID: 95232495
30. Sakai, T. et al. (1998) Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2. J Virol 72, 6034–6039, PubMed ID: 98285764
31. Kaiser, C. et al. (1999) The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 73, 4481–4484, PubMed ID: 99214394
32. Robertson, E.S. (1997) The Epstein-Barr virus EBNA3 protein family as regulators of transcription. Epstein-Barr Virus Rep 4, 143–150
33. Allday, M.J. and Farrell, P.J. (1994) Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68, 3491–3498, PubMed ID: 94246692
34. Radkov, S.A. et al. (1997) Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71, 8552–8562, PubMed ID: 98001378
35. Parker, G.A. et al. (1996) Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13, 2541–2549, PubMed ID: 97152545
36. Silins, S.L. and Sculley, T.B. (1994) Modulation of vimentin, the CD40 activation antigen and Burkitt's lymphoma antigen (CD77) by the Epstein-Barr virus nuclear antigen EBNA- 4. Virology 202, 16–24, PubMed ID: 94279136
37. Radkov, S.A. et al. (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73, 5688–5697, PubMed ID: 99292863
38. Allan, G.J. et al. (1992) Cell growth effects of Epstein-Barr virus leader protein. J Gen Virol 73, 1547–1551, PubMed ID: 92300354
39. Sinclair, A.J. et al. (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. Embo J 13, 3321–3328, PubMed ID: 94320596
40. Nitsche, F., Bell, A. and Rickinson, A. (1997) Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol 71, 6619–6628, PubMed ID: 97404672
41. Szekely, L. et al. (1993) EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A 90, 5455–5459, PubMed ID: 93296157
42. Huen, D.S. et al. (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10, 549–560, PubMed ID: 95148226
43. Eliopoulos, A.G. and Young, L.S. (1998) Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein- Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16, 1731–1742, PubMed ID: 98241177
44. Eliopoulos, A.G. et al. (1999) Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274, 16085–16096, PubMed ID: 99278371
45. Gires, O. et al. (1999) Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. Embo J 18, 3064–3073, PubMed ID: 99286230
46. Izumi, K.M. and Kieff, E.D. (1997) The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF- kappaB. Proc Natl Acad Sci U S A 94, 12592–12597, PubMed ID: 98024176
47. Devergne, O. et al. (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 16, 7098–7108, PubMed ID: 97098688
48. Eliopoulos, A.G. et al. (1999) Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 73, 1023–1035, PubMed ID: 99098989
49. Gires, O. et al. (1997) Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. Embo J 16, 6131–6140, PubMed ID: 98026889
50. Higuchi, M., Izumi, K.M. and Kieff, E. (2001) Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci U S A 98, 4675–4680, PubMed ID: 21192687
51. Hatzivassiliou, E. et al. (1998) A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J Immunol 160, 1116–1121, PubMed ID: 98230451
52. Hu, L.F. et al. (1991) Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72, 2399–2409, PubMed ID: 92013956
53. Li, S.N., Chang, Y.S. and Liu, S.T. (1996) Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12, 2129–2135, PubMed ID: 96218661
54. Khanim, F. et al. (1996) Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 88, 3491–3501, PubMed ID: 97051780
55. Santon, A. and Bellas, C. (2001) Deletions within the epstein-barr virus latent membrane protein-1 oncogene in adult ordinary, HIV-associated and paediatric Hodgkin's disease. Leuk Lymphoma 40, 235–242, PubMed ID: 21319838
56. Johnson, R.J. et al. (1998) The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J Virol 72, 4038–4048, PubMed ID: 98216770
57. Longnecker, R. and Kieff, E. (1990) A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 64, 2319–2326, PubMed ID: 90219235
58. Longnecker, R. (2000) Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 79, 175–200, PubMed ID: 20278622
59. Fruehling, S. and Longnecker, R. (1997) The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235, 241–251, PubMed ID: 97428572
60. Miller, C.L. et al. (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein- tyrosine kinases. Immunity 2, 155–166, PubMed ID: 95202591
61. Caldwell, R.G. et al. (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405–411, PubMed ID: 98439696
62. Scholle, F., Longnecker, R. and Raab-Traub, N. (1999) Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol 73, 4767–4775, PubMed ID: 99252167
63. Ikeda, M. et al. (2000) The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology 268, 178–191, PubMed ID: 20149234
64. Scholle, F., Bendt, K.M. and Raab-Traub, N. (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74, 10681–10689, PubMed ID: 20499090
65. Neri, A. et al. (1991) Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 77, 1092–1095, PubMed ID: 91137807
66. Razzouk, B.I. et al. (1996) Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 173, 529–535, PubMed ID: 96196109
67. Klein, G. (1979) The relationship of the virus to nasopharyngeal carcinoma. In The Epstein-Barr Virus (Epstein, M.A. and Achong, B.G., eds), pp. 339–350, Springer-Verlag, Berlin
68. Klein, G. et al. (1974) Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A 71, 4737–4741, PubMed ID: 75065593
69. Raab-Traub, N. and Flynn, K. (1986) The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47, 883–889, PubMed ID: 87051769
70. Yu, M.C. et al. (1986) Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res 46, 956–961, PubMed ID: 86079200
71. Zeng, Y. (1985) Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv Cancer Res 44, 121–138, PubMed ID: 85303476
72. Hsu, J.L. and Glaser, S.L. (2000) Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 34, 27–53, PubMed ID: 20245248
73. Johannessen, I., Asghar, M. and Crawford, D.H. (2000) Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br J Haematol 109, 600–610, PubMed ID: 20345415
74. Young, L. et al. (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321, 1080–1085, PubMed ID: 90014988
75. Dotti, G. et al. (2000) Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 69, 827–833, PubMed ID: 20216311
76. Nelson, B.P. et al. (2000) Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24, 375–385, PubMed ID: 20178895
77. MacMahon, B. (1966) Epidemiology of Hodgkin's disease. Cancer Res 26, 1189–1201, PubMed ID: 66172814
78. Levine, P.H. et al. (1971) Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 27, 416–421, PubMed ID: 71104690
79. Mueller, N. et al. (1989) Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 320, 689–695, PubMed ID: 89159302
80. Gutensohn, N. and Cole, P. (1980) Epidemiology of Hodgkin's disease. Semin Oncol 7, 92–102, PubMed ID: 81078840
81. Clark, D.A. et al. (1990) The seroepidemiology of human herpesvirus-6 (HHV-6) from a case-control study of leukaemia and lymphoma. Int J Cancer 45, 829–833, PubMed ID: 90243363
82. Alexander, F.E. et al. (1995) Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology in Hodgkin's disease: results of a case-control study. Eur J Cancer 9, 1479–1486, PubMed ID: 96091000
83. Levine, P.H. et al. (1994) Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int J Cancer 59, 48–50, PubMed ID: 95012851
84. Armstrong, J.A. et al. (1976) Viral infections in renal transplant recipients. Infect Immun 14, 970–975, PubMed ID: 77050638
85. Anagnostopoulos, I. et al. (1989) Demonstration monoclonal EBV genomes in Hodgkin's disease and Ki-1- positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 74, 810–816, PubMed ID: 89323433
86. Coates, P.J., Slavin, G. and D'Ardenne, A.J. (1991) Persistence of Epstein-Barr virus in Reed-Sternberg cells throughout the course of Hodgkin's disease. J Pathol 164, 291–297, PubMed ID: 92014481
87. Nerurkar, A.Y. et al. (2000) Discrepancies in Epstein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenesis. Ann Oncol 11, 475–478, PubMed ID: 20304082
88. Staratschek-Jox, A. et al. (2000) Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells: no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease. Am J Pathol 156, 209–216, PubMed ID: 20090565
89. Flavell, K.J. and Murray, P.G. (2000) Hodgkin's disease and the Epstein-Barr virus. Mol Pathol 53, 262–269, PubMed ID: 20543343
90. Niedobitek, G. and Young, L.S. (1997) Epstein-Barr virus and non-Hodgkin's lymphomas. In The Non-Hodgkin's Lymphomas (2nd edn) (Magrath, I., ed.), pp. 309–329, Arnold, London
91. Brink, A.A. et al. (2000) Epstein-Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non-Hodgkin lymphomas. J Pathol 191, 400–406, PubMed ID: 20379092
92. Niedobitek, G. et al. (2000) Hodgkin's disease and peripheral T-cell lymphoma: composite lymphoma with evidence of Epstein-Barr virus infection. J Pathol 191, 394–399, PubMed ID: 20379091
93. Gregory, C.D., Rowe, M. and Rickinson, A.B. (1990) Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71, 1481–1495, PubMed ID: 90324934
94. Niedobitek, G. et al. (1995) Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86, 659–665, PubMed ID: 95329723
95. Young, L.S. et al. (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69, 1051–1065, PubMed ID: 88229624
96. Deacon, E.M. et al. (1993) Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177, 339–349, PubMed ID: 93147723
97. Meijer, C.J. et al. (1996) Epstein-Barr virus and human T-cell lymphomas. Semin Cancer Biol 7, 191–196, PubMed ID: 97102089
98. Kerr, B.M. et al. (1992) Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187, 189–201, PubMed ID: 92142505
99. Bonnet, M. et al. (1999) Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 91, 1376–1381, PubMed ID: 99382379
100. Sugawara, Y. et al. (1999) Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 256, 196–202, PubMed ID: 99208814
101. Sample, J. et al. (1990) Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64, 4084–4092, PubMed ID: 90347798
102. Young, L.S. et al. (1987) New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol 68, 2853–2862, PubMed ID: 88061209
103. Brooks, J.M. et al. (2000) Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J Virol 74, 1801–1809, PubMed ID: 20111301
104. Papadopoulos, E.B. et al. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330, 1185–1191, PubMed ID: 94187811
105. Rooney, C.M. et al. (1998) Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr 23, 89–93, PubMed ID: 98374971
106. Hopwood, P. and Crawford, D.H. (2000) The role of EBV in post-transplant malignancies: a review. J Clin Pathol 53, 248–254, PubMed ID: 20282527
107. Wilson, A.D. et al. (1998) CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol 10, 1149–1157, PubMed ID: 98389094
108. Jin, X. et al. (1998) Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection. Eur J Immunol 28, 3564–3576, PubMed ID: 99057033
109. Wilson, A.D. et al. (2001) In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors. Clin Exp Immunol 125, 1–11
110. Munz, C. et al. (2000) Human CD4(+) T lymphocytes consistently respond to the latent Epstein- Barr virus nuclear antigen EBNA1. J Exp Med 191, 1649–1660, PubMed ID: 20273972
111. Rooney, C.M. et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555, PubMed ID: 98384217
112. Gottschalk, S. et al. (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97, 835–843, PubMed ID: 21093814
113. Herbst, H. et al. (1996) Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 87, 2918–2929, PubMed ID: 96219988
114. Frisan, T. et al. (1995) Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86, 1493–1501, PubMed ID: 95359450
115. Roskrow, M.A. et al. (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91, 2925–2934, PubMed ID: 98200599
116. Franken, M. et al. (1996) Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat Med 2, 1379–1382, PubMed ID: 97102413
117. Westphal, E.M. et al. (2000) Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 60, 5781–5788, PubMed ID: 20511581
118. Robertson, K.D. et al. (1995) Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus- associated malignancies. Curr Top Microbiol Immunol 194, 145–154, PubMed ID: 95202955
119. Cahir-McFarland, E.D. et al. (2000) NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 97, 6055–6060, PubMed ID: 20283949
120. Piche, A. et al. (1998) Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther 5, 1171–1179, PubMed ID: 99129178
121. Slobod, K.S. et al. (2000) Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 356, 1493–1494, PubMed ID: 20531789
122. Delecluse, H.J. and Hammerschmidt, W. (2000) The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol 53, 270–279, PubMed ID: 20543344
123. Jackman, W.T. et al. (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17, 660–668, PubMed ID: 99164994